"Asked about adoption in the clinic if the drug gains approval, Li said the first step will be to start testing all NSCLC patients for KRAS mutations."
KRAS Inhibitor Continues to Impress in NSCLC
Source : https://www.medpagetoday.com/meetingcoverage/iaslc/90989
More than a third of patients with pretreated non-small cell lung cancer (NSCLC) and a KRAS G12C mutation responded to the investigational agent sotorasib, findings from a phase II study...
This is scary.
“More than one in 10 patients with lung cancer do not know what type of tumour they have.”
Educated patients and shared decision making lead to greater engagement and care.
More Than One in 10 Patients With Lung Cancer Do Not Know What Type They Have [ESMO Press Release]
LUGANO, Switzerland; DENVER, CO, USA - More than one in 10 patients with lung cancer do not know what type of tumour they have, according to data from a 17-country...
KRAS(G12C)-AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations
Source : https://www.nature.com/articles/s41598-020-68950-y
The first KRAS(G12C) targeting inhibitor in clinical development, AMG 510, has shown promising antitumor activity in clinical trials. On the molecular level, however, the interaction dynamics of this covalently bound...
Abstract 1958: Repotrectinib increases effectiveness of KRAS-G12C inhibitors in KRAS-G12C mutant cancer models via simultaneous SRC/FAK/JAK2 inhibition
Source : https://cancerres.aacrjournals.org/content/80/16_Supplement/1958
Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA KRAS is frequently mutated in multiple cancer types. Therapeutic targeting of KRAS has proven challenging until...